Scholarlink

Introduction <p>Respiratory syncytial virus (RSV) infections are a leading cause of lower respiratory tract infections (LRTI), particularly bronchiolitis and pneumonia, leading to significant hospitalizations and economic burden in infants. In Colombia, RSV is endemic with high morbidity and mortality rates, underscoring the need for effective prophylactic technologies to reduce its impact.</p> Methods <p>This study aimed to analyze the health and economic impact of new RSV immunization technologies in Colombia, focusing on two interventions: nirsevimab and RSVpreF. A static cohort decision model was used to compare these interventions against the standard of care (palivizumab-SoC), estimating outcomes including hospitalizations, intensive care unit (ICU) admissions, deaths, and event-related healthcare costs. The model included outcomes such as QALYs and direct and indirect event-related costs from the third-party and societal perspectives. Acquisition costs of prophylactic interventions were not included because prices are not publicly available during ongoing negotiations.</p> Results <p>Nirsevimab was associated with a greater reduction in healthcare events and costs compared to both SoC and RSVpreF. In the base-case scenario, it prevented an additional 44,039 events and was associated with US$23.4&#xa0;million lower event-related healthcare costs compared to SoC. When compared with RSVpreF, it averted 14,558 more events and was associated with US$8.4&#xa0;million lower event-related costs. The greatest reduction occurred in primary care visits, with 32,744 and 10,458 fewer cases versus SoC and RSVpreF, respectively, followed by reductions in hospitalizations of 6210 and 2257 cases. Nirsevimab yielded up to 646 additional QALYs compared with RSVpreF and associated with up to US$25.3&#xa0;million lower event-related costs from avoided health events in societal scenarios. Sensitivity analysis identified nirsevimab efficacy and infection distribution as the key drivers of event-related cost and QALY outcomes.</p> Conclusion <p>Nirsevimab was associated with larger reductions in RSV-related events, greater reductions in event-related costs, and higher QALYs than SoC and RSVpreF. Its adoption in national immunization programs could significantly reduce the economic and disease burden of RSV and improve infant health.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Analysis of the Economic and Public Health Impact of New Immunization Strategies in Infants Against Respiratory Syncytial Virus (RSV) in Colombia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月8日

查看全文
  • Maria Carrasquilla-Sotomayor,
  • Nelson J. Alvis-Zakzuk,
  • Wilfrido Coronell-Rodríguez,
  • Andres Arias,
  • Lina Moyano-Tamara,
  • Juan Carlos Alvarado-Gonzalez,
  • Fernando De la Hoz-Restrepo,
  • Nelson Alvis-Guzman

摘要

Introduction

Respiratory syncytial virus (RSV) infections are a leading cause of lower respiratory tract infections (LRTI), particularly bronchiolitis and pneumonia, leading to significant hospitalizations and economic burden in infants. In Colombia, RSV is endemic with high morbidity and mortality rates, underscoring the need for effective prophylactic technologies to reduce its impact.

Methods

This study aimed to analyze the health and economic impact of new RSV immunization technologies in Colombia, focusing on two interventions: nirsevimab and RSVpreF. A static cohort decision model was used to compare these interventions against the standard of care (palivizumab-SoC), estimating outcomes including hospitalizations, intensive care unit (ICU) admissions, deaths, and event-related healthcare costs. The model included outcomes such as QALYs and direct and indirect event-related costs from the third-party and societal perspectives. Acquisition costs of prophylactic interventions were not included because prices are not publicly available during ongoing negotiations.

Results

Nirsevimab was associated with a greater reduction in healthcare events and costs compared to both SoC and RSVpreF. In the base-case scenario, it prevented an additional 44,039 events and was associated with US$23.4 million lower event-related healthcare costs compared to SoC. When compared with RSVpreF, it averted 14,558 more events and was associated with US$8.4 million lower event-related costs. The greatest reduction occurred in primary care visits, with 32,744 and 10,458 fewer cases versus SoC and RSVpreF, respectively, followed by reductions in hospitalizations of 6210 and 2257 cases. Nirsevimab yielded up to 646 additional QALYs compared with RSVpreF and associated with up to US$25.3 million lower event-related costs from avoided health events in societal scenarios. Sensitivity analysis identified nirsevimab efficacy and infection distribution as the key drivers of event-related cost and QALY outcomes.

Conclusion

Nirsevimab was associated with larger reductions in RSV-related events, greater reductions in event-related costs, and higher QALYs than SoC and RSVpreF. Its adoption in national immunization programs could significantly reduce the economic and disease burden of RSV and improve infant health.